Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide
- PMID: 16949586
- DOI: 10.1016/j.febslet.2006.08.030
Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide
Abstract
The relevance of a point mutation at the C-terminal end of the S6 helix (F468) and the introduction of C-type inactivation in the blockage of hEag1 channels by astemizole, imipramine and dofetilide was tested. C-type inactivation decreased block by astemizole and dofetilide but not imipramine, suggesting different binding sites in the channel. F468C mutation increased IC(50) for astemizole and imipramine but in contrast to HERG channels, only slightly for dofetilide. Together with measurements on recovery of blocking, our observations indicate that the mechanism of hEag1 blockage by each of these drugs is different, and suggest relevant structural differences between hEag1 and HERG channels.
Similar articles
-
Mechanism of block of hEag1 K+ channels by imipramine and astemizole.J Gen Physiol. 2004 Oct;124(4):301-17. doi: 10.1085/jgp.200409041. Epub 2004 Sep 13. J Gen Physiol. 2004. PMID: 15365094 Free PMC article.
-
The Link between Inactivation and High-Affinity Block of hERG1 Channels.Mol Pharmacol. 2015 Jun;87(6):1042-50. doi: 10.1124/mol.115.098111. Epub 2015 Apr 8. Mol Pharmacol. 2015. PMID: 25855787 Free PMC article.
-
Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.Toxicol Appl Pharmacol. 2014 Jan 1;274(1):78-86. doi: 10.1016/j.taap.2013.10.024. Epub 2013 Nov 5. Toxicol Appl Pharmacol. 2014. PMID: 24200993
-
Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.Biochem Pharmacol. 2009 May 15;77(10):1602-11. doi: 10.1016/j.bcp.2009.02.011. Epub 2009 Feb 27. Biochem Pharmacol. 2009. PMID: 19426697
-
Astemizole: an old anti-histamine as a new promising anti-cancer drug.Anticancer Agents Med Chem. 2011 Mar;11(3):307-14. doi: 10.2174/187152011795347513. Anticancer Agents Med Chem. 2011. PMID: 21443504 Review.
Cited by
-
3D Pharmacophore-Based Discovery of Novel KV10.1 Inhibitors with Antiproliferative Activity.Cancers (Basel). 2021 Mar 12;13(6):1244. doi: 10.3390/cancers13061244. Cancers (Basel). 2021. PMID: 33808994 Free PMC article.
-
The hEag1 K+ Channel Inhibitor Astemizole Stimulates Ca2+ Deposition in SaOS-2 and MG-63 Osteosarcoma Cultures.Int J Mol Sci. 2022 Sep 11;23(18):10533. doi: 10.3390/ijms231810533. Int J Mol Sci. 2022. PMID: 36142445 Free PMC article.
-
Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of KV10.1 Pore Blockers.Int J Mol Sci. 2021 Aug 20;22(16):8999. doi: 10.3390/ijms22168999. Int J Mol Sci. 2021. PMID: 34445705 Free PMC article.
-
Voltage-dependent gating of KCNH potassium channels lacking a covalent link between voltage-sensing and pore domains.Nat Commun. 2015 Mar 30;6:6672. doi: 10.1038/ncomms7672. Nat Commun. 2015. PMID: 25818916 Free PMC article.
-
Ion channels as therapeutic antibody targets.MAbs. 2019 Feb/Mar;11(2):265-296. doi: 10.1080/19420862.2018.1548232. Epub 2018 Dec 10. MAbs. 2019. PMID: 30526315 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases